Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems
George Doumat, Darine Daher, Morgan Bou Zerdan, et al.
Current Oncology (2023) Vol. 30, Iss. 1, pp. 704-719
Open Access | Times Cited: 19

Showing 19 citing articles:

Potential Applications of Nanoparticles in Improving the Outcome of Lung Cancer Treatment
Agnishwar Girigoswami, Koyeli Girigoswami
Genes (2023) Vol. 14, Iss. 7, pp. 1370-1370
Open Access | Times Cited: 23
Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)
Sumel Ashique, Ashish Garg, Neeraj Mishra, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 11, pp. 2769-2792
Closed Access | Times Cited: 18
Repurposing Therapeutic Drugs Complexed to Vanadium in Cancer
Ana Luísa De Sousa‐Coelho, Gil Fraqueza, Manuel Aureliano
Pharmaceuticals (2023) Vol. 17, Iss. 1, pp. 12-12
Open Access | Times Cited: 17
Repurposing Antiepileptic Drugs for Cancer: A Promising Therapeutic Strategy
Noor Tarawneh, S. A. Hussein, Shtaywy Abdalla
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2673-2673
Open Access
NSUN6 Regulates NM23-H1 Expression in an m5C Manner to Affect Epithelial-Mesenchymal Transition in Lung Cancer
Zhansheng Lu, Bo Liu, Demiao Kong, et al.
Medical Principles and Practice (2023) Vol. 33, Iss. 1, pp. 56-65
Open Access | Times Cited: 9
Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer
Juan Enrique Faya Castillo, Richard Junior Zapata Dongo, Paolo Alberto Wong Chero, et al.
PLoS ONE (2024) Vol. 19, Iss. 2, pp. e0295966-e0295966
Open Access | Times Cited: 2
XGraphCDS: An explainable deep learning model for predicting drug sensitivity from gene pathways and chemical structures
Yimeng Wang, Xinxin Yu, Yaxin Gu, et al.
Computers in Biology and Medicine (2023) Vol. 168, pp. 107746-107746
Closed Access | Times Cited: 6
Ribavirin attenuates carcinogenesis by downregulating IL-6 and IL-8 in vitro in human lung adenocarcinoma
Gabriele De Rubis, Keshav Raj Paudel, Stewart Yeung, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 155038-155038
Closed Access | Times Cited: 6
SOX2 Expression Does Not Guarantee Cancer Stem Cell-like Characteristics in Lung Adenocarcinoma
Seung-Hyun Bae, Kyung Yong Lee, Suji Han, et al.
Cells (2024) Vol. 13, Iss. 3, pp. 216-216
Open Access | Times Cited: 1
Multi-method coamorphous systems of lumefantrine with alpha ketoglutaric acid: Comprehensive characterization, biological evaluation and stability analysis
Rahul Khemchandani, Ekta Pardhi, Sridivya Goud, et al.
International Journal of Pharmaceutics (2024), pp. 125056-125056
Closed Access | Times Cited: 1
Investigating Carvedilol’s Repurposing for the Treatment of Non-Small Cell Lung Cancer via Aldehyde Dehydrogenase Activity Modulation in the Presence of β-Adrenergic Agonists
Balqis Ikhmais, Alaa M. Hammad, Osama H. Abusara, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 10, pp. 7996-8012
Open Access | Times Cited: 3
The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer
Shuangcui Wang, Guan Zhang, Qian Cui, et al.
Immunity Inflammation and Disease (2023) Vol. 11, Iss. 11
Open Access | Times Cited: 3
In Vivo Cancer Microenvironment Responsive Glycan Receptor-Targeted Nanoparticles for Gemcitabine Delivery to Benzo[a]pyrene-Induced Lung Cancer Model
Krishan Kumar, Rinki Verma, Manjit Manjit, et al.
AAPS PharmSciTech (2023) Vol. 25, Iss. 1
Closed Access | Times Cited: 3
Drug Repurposing of Mito-Atovaquone for Cancer Treatment
Nemesio Villa‐Ruano, Maricruz Anaya-Ruı́z, Luis Villafaña-Díaz, et al.
Pharmaceutical Patent Analyst (2023) Vol. 12, Iss. 4, pp. 143-149
Closed Access | Times Cited: 3
Overexpression of transcription factor TBX5 inhibits the activation of YAP1-TEAD1 pathway to promote ferroptosis in lung cancer cells
R. Ma, Ke Hu, Siyuan Dai, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 718, pp. 150037-150037
Closed Access
Clinical Trials on Repurposed Drugs: An Overview
Ruchira Patil, Harshad Takate, Gaurav Shanbhag, et al.
Drug repurposing (2024), pp. 173-199
Closed Access
Drug Repurposing of Rimantadine for Treatment of Cancer
Nemesio Villa‐Ruano, Vianey Marín-Cevada, Gabriela Sánchez-Esgua, et al.
Pharmaceutical Patent Analyst (2023) Vol. 12, Iss. 5, pp. 231-236
Closed Access | Times Cited: 1
Design and Discovery of Genistein-based Drugs as a Potential Tyrosine Kinase Inhibitor for Lung Adenocarcinoma through Hybrid In-silico Methods
Vijay Wakale, Ramanlal N. Kachave, Pranjal Gholap, et al.
International Journal of Drug Delivery Technology (2023) Vol. 13, Iss. 04, pp. 1422-1427
Open Access | Times Cited: 1
BioNet+: A Comprehensive Interaction Model of Finding Therapeutics for Diseases with Graph Deep Learning
Jing-Lun Ma, Yanlong Qiu, Canqun Yang, et al.
(2023)
Closed Access
Development and evaluation of flubendazole inhalable nanoparticles for lung cancer treatmen
Mariana Yasue Saito Miyagi
(2023)
Open Access
Page 1

Scroll to top